Table 4.

Complete responses to dasatinib.

	SM		AML	HES
	SM-PMF	SM-CEL
Patient characteristics	61-year-old white male, diagnosed with SM-PMF in 6/2005 Anemia, SOB, fatigue, back pain	64-year-old African American male, diagnosed with SM-CEL in 9/2005 Anemia, SOB, fatigue, low-grade fever, sweating, loss of weight	80-year-old white male, diagnosed with AML in 11/2005	48-year-old white female, diagnosed with HES in 1/2001 Rash, SOB, diarrhea, fatigue
Prior therapy	Darbepoetin x 5 months without result	Epoetin alfa x 4 months without result	Daunorubicin + cytarabine with short complete response (1 month)	Prednisone, imatinib, hydroxyurea
Baseline laboratory values	Hb: 9.4 g/dL Plt: 90 × 109/L WBC: 4.4 × 109/L 6% blasts Tryptase 22 ng/mL	Hb: 9.4 g/dL Plt: 150 × 109/L WBC: 8.3 × 109/L Eos: 13%, AEC: 1.08 x109/L Tryptase 13 ng/mL	Hb: 11.8 g/dL Plt: 604 × 109/L WBC: 6.9 × 109/L No blasts	Hb 13.3 g/dL Plt: 299 × 109/L WBC: 9.4 × 109/L Eos: 28%, AEC: 2.63 × 109/L
Baseline BM, cytogenetics, and gene analysis	4% blasts 10–15% MC on biopsy Reticulin 2+ (scale 0–3) Cyto: 47, XY, +1, der(1;7) (q10;p10), +9 [10/20] KIT-D816V-negative JAK2-V617F-positive	20% Eos 10–20% MC on biopsy; insufficient metaphases on cyto analysis, but t(5;12) (q33;q13) after one year of therapy KIT-D816V-negative, PDGFRα-negative, JAK2-V617F-negative	13% blasts Cyto: +8 [2/20]	20% Eos Diploid cytogenetics KIT-D816V-negative PDGFRα-negative
Dasatinib dose	70 mg twice daily	70 mg twice daily; −1 level due to pleural effusion; −2 level due to fatigue	70 mg twice daily; −1 level due to rash; −2 level due to rash	70 mg twice daily; −1 level due to nausea/vomiting, headache and rash; stopped therapy due to pleural effusion
Response to dasatinib	Starting at 3 weeks:  Plt ≥148 × 109/L Starting at 6 months:  Hb: ≥10.1 g/dL BM at 3 and 6 months:  Hypocellular  No SM  Reticulin 4+  Blasts 4%	Starting at 2 months:  Hb: 13.0 g/dL  WBC: 7.4 × 109/L  Eos: 3.9% BM at 3, 6, 9, 12, and 15 months:  Eos ≤4%  No SM  Normal cellularity	At 2 months:  BM: 3% blasts  Normal cyto  Hb: 13.7 g/dL  Plt: 223 × 109/L  WBC: 6 × 109/L	Starting at 1 week:  ≤4% Eos in blood At 3, 6, and 12 months:  ≤4% Eos in BM
Outcome	Died after 8 months due to AML	Died off therapy (due to other medical reasons) after 18 months	Cytogenetic relapse after 6 months (+8 [16/20]); AML relapse after 15 months (BM: 10% blasts)	Relapsed after 14.5 months while off therapy

Abbreviations: AEC = absolute eosinophil count; AML = acute myeloid leukemia; BM = bone marrow; CEL = chronic eosinophilic leukemia; Cyto = cytogenetics; Eos = eosinophils; Hb = hemoglobin level; HES = hypereosinophilic syndrome; MC = mast cells; PMF = primary myelofibrosis; Plt = platelet count; SM = systemic mastocytosis; SOB = shortness of breath; WBC = white blood cell count